We don't expect Abbott's (NYSE: ABT) revenue to grow in double-digits in the near term. The company has seen its revenue grow at a CAGR of 12.4% from $20.4 billion in 2015 to $31.9 billion in 2019, but this growth was largely driven by the impact of St Jude Medical as well as Alere acquisitions...
We don't expect Abbott's (NYSE: ABT) revenue to grow in double-digits in the near term. The company has seen its revenue grow at a CAGR of 12.4% from $20.4 billion in 2015 to $31.9 billion in 2019, but this growth was largely driven by the impact of St Jude Medical as well as Alere acquisitions...
Share this Article
Recommended